title: [Laboratory and clinical studies on combined effects of fosfomycin plus sulbactam/cefoperazone for mixed infections of MRSA and Pseudomonas aeruginosa].
abstract: The time-lag/sequential/step by step chemotherapy by fosfomycin plus sulbactam/cefoperazone including a short time small dose of steroid was done for 27 severely infected patients suffered from various cancer or other severe basal diseases. And the staggered "intensive" chemotherapy with added arbekacin or vancomycin to the previous staggered chemotherapy was done against 13 severely infected patients having MRSAs among their infecting pathogens. 1. Bacteriological effects Pseudomonas aeruginosa 6/8, Staphylococcus epidermidis 5/5, Enterococcus faecalis 3/6, Acinetobacter calcoaceticus 2/2, Klebsiella pneumoniae 2/2, MRSA 2/2, Xanthomonas maltophilia 2/3 and other 10/10 were eradicated (84.2%) by the staggered chemotherapy and MRSA 7/13, P. aeruginosa 3/4, E. faecalis 3/5, A. calcoaceticus 2/2, X. maltophilia 1/1 and others 2/2 were eradicated (53.8% in MRSA, 78.6% in others and 66.7% in total) and 3 of MRSAs were colonized. 2. Clinical effects 1) Staggered chemotherapy: Excellent 18/27, good 8/27, fair 1/27, poor 0/27 (96.3%). 2) Staggered "intensive" chemotherapy: Excellent 6/13, good 4/13, fair 2/13, poor 1/13 (76.9%) in total: excellent 60.0%, efficacy rate 90.0%.
authors.affiliation: Pharmaceutical Research Center, Meiji Seika Kaisha Ltd.
authors.forename: I
authors.initials: I
authors.lastname: Hayashi
authors.forename: M
authors.initials: M
authors.lastname: Sakurai
authors.forename: A
authors.initials: A
authors.lastname: Karato
authors.forename: M
authors.initials: M
authors.lastname: Ichiki
authors.forename: I
authors.initials: I
authors.lastname: Sekine
authors.forename: T
authors.initials: T
authors.lastname: Ishikawa
authors.forename: J
authors.initials: J
authors.lastname: Shiotani
authors.forename: T
authors.initials: T
authors.lastname: Yoshida
authors.forename: M
authors.initials: M
authors.lastname: Niida
authors.forename: M
authors.initials: M
authors.lastname: Ogawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D002438:Cefoperazone / Q000627:therapeutic use; D003982:Dibekacin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005260:Female; D005578:Fosfomycin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D016106:Methicillin Resistance; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*; D013407:Sulbactam / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005578:Fosfomycin; D003982:Dibekacin; D014640:Vancomycin; D002438:Cefoperazone; C031986:arbekacin; D013407:Sulbactam